# Year in Review 2018-2019



Redefining possible."

Brad Sharpe, MD SFHM Brad Monash, MD SFHM

## Year in Review 2019

- Updated literature
- September 2018 September 2019

#### Process:

- CME collaborative review of journals
  - Including ACP J. Club, J. Watch, etc.
- Independent analysis of article quality

Chose articles based on 3 criteria:

- 1) Change your practice
- 2) Modify your practice
- 3) Confirm your practice
- Hope to <u>not</u> use the words:
  - Student's t-test, meta-regression, Mantel-Haenszel statistical method, etc.
  - Focus on breadth, not depth

## Year in Review 2019

- Major reviews/short takes
- Case-based format
- Multiple choice questions
- Promote retention

# Syllabus/Bookkeeping



No conflicts of interest

Final presentation available by email:

sharpeb@medicine.ucsf.edu

Year in Review

# **De-Escalation in Pneumonia**

- A total of 279 patients
- Most in the ICU (87%), 56% VAP
- A total of 92 (33.0%) had de-escalation
- No clinical difference between the two groups

Outcome	De-escalation	No	р
Length of Stay (days)	15	20	<0.05
Acute Kidney Injury	36.2%	50.0%	<0.05
Mortality (28-day)	22.8%	28.3%	NS

Cowley MC, et al. CHEST.2019;155(1):53-59.

# **De-Escalation in Pneumonia**

- Question: In HAP, is it safe to "de-escalate" MRSA coverage if cultures are negative?
- Design: Single-center, retrospective; nosocomial pneumonia & negative cultures
- Conclusion: No harm to de-escalating MRSA coverage; Shorter LOS, less AKI, no change in mortality
- Comments: Retrospective study, confounder?
  - Appears no harm, potential benefit to deescalation;
  - Not much data otherwise;
  - Seems reasonable to stop in most patients

## Short take: Nutrition in the Hospital

- In a randomized controlled trial of patients at nutritional risk (high NRS scores), 2088 patients were randomized to:
  - Individualized nutrition support
    - $\geq$  75% of caloric and protein needs
    - Micronutrients
    - Use enteral or parenteral nutrition if needed
  - No dietary consultation

Scheutz P, et al. Lancet. 2019;393:2312.

#### Short take: Nutrition in the Hospital

Outcome	Nutrition	No	р
Adverse Outcome (30d)	23%	27%	0.02
Mortality (30d)	7%	10%	0.01

- Improve quality of life at 30 days
- No impact on length of stay
- No adverse side effects

Scheutz P, et al. Lancet. 2019;393:2312.

#### Short take: Overdiagnosis of COPD

- Large global database of adults (16,177 pts.)
- A total of 919 self-reported a diagnosis of COPD
- All patients got spirometry
- Overdiagnosis rate = **61.9%** 
  - No obstruction on post-bronchodilator spirometry
- Predictors of overdiagnosis: women, higher education, respiratory symptoms
- Nearly 50% of overdiagnosed patients were on medications

Sator L, et al. CHEST. 2019 Jan 31.

## **Increasing Blood Pressure Medications**

- Question: What is the impact of "intensifying" antihypertensive regimens at discharge?
- Design: Retrospective cohort study; VA database Intensification vs. none, propensity matched
- Conclusion: Intensification leads to readmissions & serious adverse events; no change in CV outcomes at 1 year
- Comments: Retrospective study, confounder?

Intensification likely leads to harm, no clear benefit; acute hypertension common in the hospital – treatment can cause harm; Generally avoid adjusting HTN regimens

Anderson TS, et al. JAMA Intern Med.2019; Aug 19 epub.

## Short take: Afib and Stable CAD

#### Methods:

- Multi-center, open-label RCT
- Diagnosis of afib and stable CAD (PCI or MI > 1 year prior)
- Randomized to:
  - Rivaroxaban
  - Rivaroxaban + aspirin (or P2Y<sub>12</sub> inhibitor)

Yasuda S, et al. NEJM. 2019;381:1103.

## Short take: Afib and Stable CAD

#### Results:

Outcome	Rivaroxaban	Rivaroxaban + ASA	р
CV Event or Death	4.14%	5.75%	<0.01
Major Bleeding	1.62%	2.76%	0.01

For most patients with afib and *stable* CAD, go with monotherapy with a DOAC

Yasuda S, et al. *NEJM.* 2019;381:1103.

## **Case Summary**

#### <u>Consider</u>

- 1. De-escalating MRSA covering in patients with HAP and negative cultures at 48 hours.
- 2. Consulting nutrition in patients at nutritional risk.
- 3. COPD may be overdiagnosed (~ 60%).
- 4. Avoiding increasing BP meds in the hospital.
- 5. In patients with afib and stable CAD on a DOAC, stop the aspirin.

## Short Take: ED Crowding, D/C & Mortality

- Registry study of patients ≥ 18y assigned as low triage acuity who were discharged from ED
- Divided into surviving (n=705,076) or dying (n=623) within 10 days
- Multivariable logistic regression analyses

Patients discharged during high ED occupancy had increased 10-day mortality (OR ~1.5)

Berg LM, et al. Ann Emerg Med. 2019;74(3):345-56

# Antipsychotics for Delirium

#### Key Findings:

- No difference vs. placebo: (low-mod evidence)
  - Sedation status
  - Length of stay
  - Delirium duration\*
  - Mortality\*\*

\*Meta-analysis of 4 RCTs (non-ICU) with 0.2d increase \*\*1 RCT haloperidol in pall care with increased mortality

Nikooie, R et al. Ann Intern Med. 2019;171:485-95

# Antipsychotics for Delirium

#### Key Findings:

Insufficient/inconsistent evidence:

- Cognitive function
- Delirium severity
- Inappropriate continuation

Increased QTc for several agents

No difference in neuro AEs

Nikooie, R et al. Ann Intern Med. 2019;171:485-95

# Antipsychotics for Delirium

- Question: What are the benefits and harms of using antipsychotics to treat inpatient delirium?
- Design: Systematic review, 26 trials (16 RCTs, 10 obs) 5607 hospitalized patients with delirium
- **Conclusion:** Current evidence does not support routine use of antipsychotics to treat delirium.
- Comments: Heterogeneity (i.e., dose, frequency, route) Variable outcomes, delirium type, instruments Inclusion of ICU patients -> generalize? Exclusion of pts with neuro + CV issues

Nikooie, R et al. Ann Intern Med. 2019;171:485-95

## Short Take: 7 vs 14 days in GNR bacteremia

Outcome	<b>7</b> d	<b>14d</b>	Р
Composite	<b>46%</b>	48%	NS
Mortality (90d)	12%	11%	NS
Readmissions	39%	43%	NS
Long stay >14d	5%	6%	NS
Distant complications	3%	3%	NS
Bacteremia relapse	5%	3%	NS
Suppurative complications	5%	3%	NS

\*Shorter course: Quicker return to baseline function

Yahav D, et al. *Clin Infect Dis*. 2019;69(7):1091-8

#### Short Take: 7 vs 14 days in GNR bacteremia

Practice Changing A 7 day course of antibiotics is sufficient for:

- Patients with <u>Enterobacteriaceae</u> bacteremia
- Urinary source
- Have source control
- Clinically stable by day 5
- Unanswered questions:
  - What about non-urinary source? (probably)
  - What about ESBL? (possibly but MERINO trial used 14d)
  - When can you switch to orals?
  - Can you use an oral beta-lactam?

# Patients' Values & Preferences



- 26% contained <u>no</u> information exchange or deliberation about pt values and preferences.
- 56% contained <u>no</u> discussion about applying pts' values and preferences in the current situation

Scheunemann LP, et al. JAMA Intern Med. 2019;179(5):676-84

# Patients' Values & Preferences

#### On the flipside:

- Only 5-7% addressed patient response to living with prolonged physical or cognitive/emotional impairment
- Only 8% included clinician recommendations based on patient values and preferences

Scheunemann LP, et al. JAMA Intern Med. 2019;179(5):676-84

# Patients' Values & Preferences

- Question: How often do clinicians ask about patients' expressed values and preferences in the ICU?
- Design: Prospective cohort study, 244 recorded GOC discussions in 13 ICUs.
- Conclusion: Most GOC discussions with surrogates for critically-ill patients do not incorporate patients' values and preferences.

Comments: Only 1 conference recorded per patient Hawthorne effect may lead to overestimation English-speaking surrogates only Generalizability?

Scheunemann LP, et al. JAMA Intern Med. 2019;179(5):676-84

## **Case Summary**

#### <u>Consider</u>

- 1. High ED occupancy may increase mortality risk.
- 2. Avoiding routine use of antipsychotics to manage inpatient delirium
- 3. In stable patients with GNR bacteremia, deescalating antibiotics by 48 hours
- 4. Treating patients with GNR bacteremia who are improving with 7 days of antibiotics.
- 5. Inquiring about patient values and beliefs and using them.

# Year in Review 2018-2019



Redefining possible."

Brad Sharpe, MD SFHM Brad Monash, MD SFHM